Announcements Trials
Browse Landscape

Phase

Phase 2 54Phase 1 22Phase 3 20Phase 1/2 11Phase EARLY_PHASE1 6Phase 4 4Phase 2/3 2Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1

Interventions

Blood Specimen Collection 34Methods 25Early Intervention, Educational 24Standard of Care 21Colposcopy 21Surveys and Questionnaires 19Educational Status 18Sentinel Lymph Node Biopsy 17Cisplatin 17Counseling 16Brachytherapy 16Exercise 15Interviews as Topic 13Carboplatin 13Therapeutics 12Surgical Procedures, Operative 11Paclitaxel 11Magnetic Resonance Spectroscopy 11Indocyanine Green 11Biopsy 11Radiotherapy 10Practice Guidelines as Topic 10Palliative Care 10Human Papillomavirus DNA Tests 10Behavior Therapy 10Specimen Handling 9Radiotherapy, Intensity-Modulated 9Psychiatric Rehabilitation 9Lymph Node Excision 9Genetic Testing 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × olaparib × Gynecologic × Clear all
NCT02681237 2022-05-09

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

University Health Network, Toronto

Phase NA Completed
34 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡